Australia's Control Bionics climbs on supply agreement with Double R&D

Control Bionics

11/04/2022 07:00

** Shares of Control Bionics  CBL.AX  rise as much as 11.4%
to A$0.39, hitting their highest since March 30 
    ** Co set for best day since Dec 16, if gains hold
    ** The speech-generating devices maker says it entered an 
agreement with assistive technology distributor Double R&D Co
Ltd  urn:newsml:reuters.com:*:nFWN2W700U
    ** Under agreement, co appoints Double R&D as the exclusive
distributor in Japan of NeuroNode Trilogy and any other CBL
products, which CBL and Double R&D subsequently agree
    ** Stock down 8.2% this year, as of last close 
    


 (Reporting by Navya Mittal in Bengaluru)
 ((navya.mittal@thomsonreuters.com))